Table II.

Treatment transition to berotralstat

Patient no.	Previous LTP for HAE	Description of transition	Berotralstat monotherapy after transition	AEs during transition
1	Tranexamic acid, lanadelumab	Lanadelumab stopped 15 days before berotralstat introduced. Tranexamic acid is increased (from 2 × 500 mg per week to 500 mg every other day)	No	None
2	Tranexamic acid 1 g 3 or 4 times a day	Tranexamic acid was weaned down 1 week after initiating berotralstat, reduced to 1 g per day gradually over 1 month, then stopped	No	None
3	Tranexamic acid 1 g 3 times a day	Tranexamic acid stopped immediately	Yes	None
4	Androgens, tranexamic acid	Tranexamic acid stopped immediately	Yes	None
5	Tranexamic acid, lanadelumab	Discontinuation of lanadelumab 4 months before berotralstat initiation	Yes	Nausea for first 2 weeks, then mild nausea and chronic diarrhea that did not require any symptomatic treatment
6	Tranexamic acid	Tranexamic acid withdrawn abruptly after ischemic stroke; initiation of berotralstat after resurgence of attacks 6 months later	Yes	None